Uno studio di fase 1/2a randomizzato, in doppio cieco, controllato con placebo, sull'allocetra intrarticolare nell'osteoartrosi del ginocchio
This is a double blind, randomized,multi-center study to evaluate the safety and efficacy of intra-articular administration of Allocetra compared to placebo in patients with symptomatic knee osteoarthritis.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
Knee osteoarthritis is a degenerative disease driven by physical breakdown of the joint cartilage, together with a chronic inflammation within the knee space. Over time, many patients will develop worsening pain in the joint and functional impairment, which may ultimately require knee replacement.
Allocetra is an immunomodulatory cell-based therapy consisting of allogeneic peripheral blood mononuclear cells that have been modified to be engulfed by macrophages and reprogram them into their homeostatic state.
This Phase 1/2a study is comprised of an open-label safety run-in stage to characterize safety and tolerability of repeated injections of Allocetra to a target knee , followed by a double-blind randomized stage to evaluate the safety and efficacy of Allocetra repeated injections to the target knee compared to placebo, in moderate to severe knee osteoarthritis patients. Patients in both stages will be followed for up to a year following last treatment. the last treatment.
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Fase
Fase
- Fase 2
- Fase 1
Contatti e Sedi
Luoghi di studio
-
-
-
Gandrup, Danimarca, 9362
- Sanos Clinic Nordjylland
-
Herlev, Danimarca, 2730
- Sanos Clinic Herlev
-
Vejle, Danimarca, 7100
- Sanos Clinic Syddanmark
-
-
-
-
-
Ashkelon, Israele, 7830604
- Barzilai Medical Center
-
Haifa, Israele, 7651211
- Rambam Medical Center
-
Petah Tikva, Israele, 4937211
- Hasharon Medical Center
-
Ramat Gan, Israele, 5266202
- Sheba Medical Center
-
Rehovot, Israele, 7661041
- Kaplan Medical Center
-
Tel Aviv, Israele, 6423906
- Ichilov - Tel Aviv Sourasky Medical Center
-
-
-
-
-
Chisinau, Moldavia, 2025
- IMSP Institutul de Cardiologie
-
Chisinau, Moldavia, 2025
- Spitalul Clininc Republican "T. Mosneaga"
-
Chisinau, Moldavia, 2068
- IMSP Sptalul Clinic Municipal "Sfanta Treime"
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Age 45 - 80 years.
- Chronic osteoarthritis of index knee with knee-related joint pain
- Radiographic evidence of knee osteoarthritis of K-L Grade 2 or 3 in the index knee.
- Knee pain assessed daily over a period of 7 days during the screening period and following wash-out of pain medications
- Patients with chronic knee pain for at least 3 months who have failed to respond adequately to conventional therapy.
- Willing to abstain from other intra-articular treatments and adhere to the protocol restrictions for concomitant medications and therapies during the study.
- Women of childbearing potential and all men must agree to use 2 methods of an adequate contraception prior to study entry and for the duration of study participation through 4 weeks following IP administration.
Exclusion Criteria:
- Wheelchair bound.
- Immunosuppressive therapy
- Any known current or prior tumor of the index knee.
- Any known history or current intra-articular or osseous infection of the index knee.
- Any evidence of clinically significant active infection
- Any known history of inflammatory arthropathy or crystal-deposition arthropathy
- Any known severe systemic cartilage and/or bone disorder, such as, but not limited to, chondrodysplasia, osteogenesis imperfecta.
- Body Mass Index (BMI) >40.
- Any major surgical cartilage treatment within 6 months
- Any ligamentous repair or malalignment correction in the index knee within 6 months
- Major injury to the index knee, such as torn ligament or severe sprain within 6 months
- Clinically relevant knee instability of the index knee
- Severe hip osteoarthritis ipsilateral to the index knee.
- Clinically significant widespread pain syndromes, e.g., fibromyalgia, long COVID syndrome.
- Known coagulopathy, or use of anticoagulation medication or antiaggregant medication;.
- certain tumors, severe cardiac, respiratory or hematologic diseases as defined in the protocol
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Doppio
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Altro: Safety run-in phase - Allocetra increasing dose
An open-label dose escalation phase to characterize the safety and tolerability of Allocetra injections to the knee in different doses and select the Allocetra dose and regimen for the randomized phase. |
Allocetra-OTS is a cell-based therapy consisting of non-HLA-matched allogeneic peripheral blood mononuclear cells, induced to an apoptotic stable state |
|
Comparatore placebo: Randomization phase - Placebo.
Three intra-articular injections of placebo into the index knee. |
The control used in this study will be placebo. Placebo solution containing all excipients except for the Allocetra cells. |
|
Sperimentale: Randomization phase - Allocetra
Three intra-articular injections of Allocetra at a selected dose, into the index knee. |
Allocetra-OTS is a cell-based therapy consisting of non-HLA-matched allogeneic peripheral blood mononuclear cells, induced to an apoptotic stable state |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Treatment-emergent adverse events and Serious adverse events following Allocetra-OTS injection
Lasso di tempo: 7 months following Day 0
|
Number and severity of adverse events (AEs), serious adverse events (SAEs) and treatment disruptions/ discontinuations throughout the study from Day 0 and up to 6 months following the last injection |
7 months following Day 0
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Weekly average of knee pain.
Lasso di tempo: 4 months and 7 months following Day 0.
|
Evaluation of change from baseline in weekly average of knee pain as measured using NRS (Numeric Rating Scale ) assessed at 3 months and 6 months from last study treatment. Scores range from 0-10 points, with higher scores indicating greater pain intensity |
4 months and 7 months following Day 0.
|
|
Change from baseline in WOMAC total score.
Lasso di tempo: 4 months, 7 months and 13 months following Day 0.
|
Change from baseline in Western Ontario and McMaster Universities Arthritis Index (WOMAC) total score at 3 months, 6 months, and 12 months from last study treatment administration. Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations. |
4 months, 7 months and 13 months following Day 0.
|
|
Change in quality of life- Euro Quality of Life-5-dimension (EQ-5D) questionnaire
Lasso di tempo: 4 months, 7 months and 13 months following Day 0.
|
Change from baseline in QoL as measured by Euro Quality of Life-5-dimension (EQ-5D) questionnaire at 6 months and at 12 months from last study treatment administration. |
4 months, 7 months and 13 months following Day 0.
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Investigatori
Investigatori
- Direttore dello studio: Lital Weinfeld-Bergman, Senior Director of Clinical Operations
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Effettivo)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- ENX-CL-05-001
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .